{"id":111019,"title":"AstraZeneca enhances its earnings amid the emergence of legal proceedings related to vaccines.","publisher":"Share Talk","author":"sharetalk","published":"2023-11-09T08:05:39+00:00","modified":"2023-11-09T08:05:39+00:00","canonical_url":"https://www.share-talk.com/astrazeneca-enhances-its-earnings-amid-the-emergence-of-legal-proceedings-related-to-vaccines/","markdown_url":"https://www.share-talk.com/astrazeneca-enhances-its-earnings-amid-the-emergence-of-legal-proceedings-related-to-vaccines.md","json_url":"https://www.share-talk.com/astrazeneca-enhances-its-earnings-amid-the-emergence-of-legal-proceedings-related-to-vaccines.json","category":"Blogs","categories":["Blogs","Health","Pharmaceutical"],"tags":["Alexion","AstraZeneca","AZN","BRITAIN","COVID-19","FDA","infections","mRNA","Oxford University","Pascal Soriot","Pfizer","pharmaceutical","United Kingdom","USA","Vaccine","Vaccines"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/07/AstraZeneca-subsidiary-finalizes-a-US1bn-deal-with-Pfizer-for-rare-diseases.jpg?fit=1200%2C800&quality=89&ssl=1","format":"news","language":"en-GB","content":"AstraZeneca surpassed profitability expectations as it disclosed its third-quarter earnings, even as it confronts a significant legal challenge alleging that the effectiveness of its vaccines was greatly exaggerated.\n\nThe pharmaceutical giant reported core earnings per share of $1.73 for the quarter, an increase from $1.67 the previous year and slightly above the anticipated $1.72. For the first nine months, core earnings per share rose by 17 percent to $5.80.\n\nAstraZeneca has raised its full-year outlook, projecting that its total revenue will grow by a mid-single-digit percentage, and when excluding Covid-related products, by a low-teen percentage.\n\nDespite a $2.9 billion (£2.4 billion) drop from Covid-related products, total revenue reached $33.8 billion (£27.5 billion), a 5 percent increase.\n\nThe Telegraph has uncovered that the company is facing a lawsuit in the High Court concerning its Covid vaccine. This case could set a precedent for up to 80 further compensation claims, potentially amounting to around £80 million."}